• Mutation; HGNC; HGNC:3236; EGFR; Unexplicit; Ex19del; Zygosity=Unspecified (PubMed=25758528).
  
• Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Heterozygous (PubMed=25758528).
  

PubMed=25758528; DOI=10.1038/ncomms7377; PMCID=PMC4357281
Niederst M.J., Sequist L.V., Poirier J.T., Mermel C.H., Lockerman E.L., Garcia A.R., Katayama R., Costa C., Ross K.N., Moran T., Howe E., Fulton L.E., Mulvey H.E., Bernardo L.A., Mohamoud F., Miyoshi N., VanderLaan P.A., Costa D.B., Janne P.A., Borger D.R., Ramaswamy S., Shioda T., Iafrate A.J., Getz G., Rudin C.M., Mino-Kenudson M., Engelman J.A.
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Nat. Commun. 6:6377.1-6377.10(2015)

PubMed=25964297; DOI=10.1158/1078-0432.CCR-15-0560; PMCID=PMC4587765
Niederst M.J., Hu H.-C., Mulvey H.E., Lockerman E.L., Garcia A.R., Piotrowska Z., Sequist L.V., Engelman J.A.
The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies.
Clin. Cancer Res. 21:3924-3933(2015)

PubMed=26828195; DOI=10.1038/nm.4040; PMCID=PMC4900892
Hata A.N., Niederst M.J., Archibald H.L., Gomez-Caraballo M., Siddiqui F.M., Mulvey H.E., Maruvka Y.E., Ji F., Bhang H.-e.C., Krishnamurthy Radhakrishna V., Siravegna G., Hu H.-C., Raoof S., Lockerman E.L., Kalsy A., Lee D., Keating C.L., Ruddy D.A., Damon L.J., Crystal A.S., Costa C., Piotrowska Z., Bardelli A., Iafrate A.J., Sadreyev R.I., Stegmeier F., Getz G., Sequist L.V., Faber A.C., Engelman J.A.
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.
Nat. Med. 22:262-269(2016)